Dr Angus Cameron

BSc, MSc, PhD
Early Career Researcher - Lecturer
This email address is being protected from spambots. You need JavaScript enabled to view it.

QMUL Directory

Protein kinases represent the largest group of drug targets in cancer therapy.

My research focuses on kinases regulating cancer cell growth and motility to understand how and when to target them with drugs.

Research Details

The targeting of protein kinases represents an opportunity and challenge in cancer treatment. Some 2% of transcribed genes are kinases, many implicated in tumorigenesis and all potentially druggable due to their nucleotide binding pocket.

My research encompasses various cancer associated kinases, including PKC, PKN, mTOR and EGFR family tyrosine kinases. In particular, my work on PKC and the HER family of tyrosine kinase growth factor receptors has revealed that inhibitors can have surprising allosteric effects on kinase function with significant implications for therapy.

My group is currently examining the role of the PKN kinases in malignant progression. PKN kinases are effectors of Rho family GTPases, regulating cell shape, adhesion and motility. I have recently been focusing on a key role for PKN family members in mammalian development where they regulate morphogenetic cell movement and angiogenesis.

We have recently described a key non-redundant role for the PKN2 isoform in the regulation of embryonic mesoderm expansion and migration. Such developmental regulators are often subverted in cancer.

The PKN kinases are dramatically upregulated in many cancers and high expression has been correlated with metastatic disease – the spread of cancer around the body. Here PKN is thought to play a role in cell motility and invasion. We have now developed the tools necessary to assess the in vivo roles of the PKN family in cancer models. Recent studies focus on the stromal roles for the PKN kinases in pancreatic and breast cancer, supported by the novel roles we have discovered for PKN during development.

The ultimate goal of this research is to assess whether these kinases represent a significant cancer drug target.


I completed my BSc in biochemistry at the University of Bath in 1995. During my undergraduate degree I got my first taste of research, working for a year in the US on protein phosphatases and virology.

I studied for my PhD in Glasgow on a Wellcome Trust Prize studentship working on receptor mediated signal transduction, graduating in 2000.I continued in Glasgow for a further 2 years on a WellcomeTrust postdoctoral fellowship.

In 2003 I joined Professor Peter Parker’s lab at the Cancer Research UK London Research Institute where I studied the role PKC family protein kinases in development and cancer. In May 2013.

I joined Barts Cancer Institute as an Early Career Researcher in the Centre for Tumour Biology.


I am supported by an Early Career Researcher fellowship funded by a HEFCE award to the Barts Cancer Institute.

Cancer Research UK support my tumour model work.

Grants as Principal Investigator

  • Breast Cancer Now – Pilot grant: £25,000
  • Royal Society, 2015–2016: £15,000
  • Pancreatic Cancer UK – Innovation award, 2015–2016: £72,000
  • Rosetrees Trust, 2015 – Sept 2018: £24,000

Key Publications

Quetier I, Marshall JT, Lachmann S, Casamassima A, Spencer-Dene B, Franco C, Worrall J, Rajeeve V, Howell M, Rosewell I, Cutillas P, Gerhardt H, Parker PJ, & Cameron AJ. Knockout of the PKN family of Rho effector kinases reveals a non-redundant role for PKN2 in developmental mesoderm expansion. Cell Reports. 2016 Jan 6. pii: S2211-1247(15) 01490-4. PMID: 26774483

Linch M, Sanz-Garcia M, Rosse C, Riou P, Peel N, Madsen C, Sahai E, Downward J, Khwaja A, Dillon C, Roffey J, Cameron AJ, Parker PJ. Regulation of polarized morphogenesis by protein kinase C iota in oncogenic epithelial spheroids. Carcinogenesis. 2014 Feb;35(2) 396-406. PMID: 24072773

Cameron AJ, Linch MD, Saurin AT, Escribano C, Parker PJ. mTORC2 targets AGC kinases through Sin1-dependent recruitment. Biochem J. 2011 Oct 15;439(2):287-97. PMID: 21806543 Cameron AJ, Escribano C, Saurin AT, Kostelecky B, Parker PJ. PKC maturation is promoted by nucleotide pocket occupation independently of intrinsic kinase activity. Nat Struct Mol Biol. 2009;16(6):624-30 PMID: 19465915

Further Publications

Additional publications are available here

Protein kinases represent the largest group of drug targets in cancer therapy.

My research focuses on kinases regulating cancer cell growth and motility to understand how and when to target them with drugs.

External Activities

  • Biochem Journal - Editorial Advisory Panel


See other researchers working on:

Angiogenesis Cell Signalling Metastasis and Invasion
This site uses cookies in order to function properly. By continuing to browse, you agree that we can save them on your device. Privacy Policy.